IGF::OT::IGF HTS TO IDENTIFY INHIBITORS OF HIV-1 CAPSID DIMERIZATION

IGF::OT::IGF HTS 鉴定 HIV-1 衣壳二聚化抑制剂

• 批准号: 9363269
• 负责人: ROGER PTAK
• 金额: $ 100万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-15 至 2018-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9363269
• 关键词: Academia; Biochemical; Biological Assay; Capsid; Cells; Chemicals; Contracts; Data; Development; Dimerization; Funding; Gene Expression; HIV; HIV Infections; HIV-1; Investigational New Drug Application; Libraries; Local Microbicides; National Institute of Allergy and Infectious Disease; Private Sector; Public Health; Research Personnel; Services; Source; Testing; Therapeutic; base; high throughput screening; inhibitor/antagonist; novel therapeutics; phase I trial; pre-clinical; product development; prospective; public health priorities

The development and introduction of new therapeutics and topical microbicides against HIV remains a high public health priority. To assist in filling these public health gaps, the NIAID supports preclinical development of promising therapeutic and topical microbicide candidates that emerge from academia, the private sector, or other sources. This contract provides product development services utilizing biochemical and cell-based assays in both standard and high throughput screening (HTS) formats. The services provided under this contract will assist a wide variety of investigators in obtaining critical data needed to acquire additional funding, gain prospective partnerships (either for further development or to support Phase I trials), and fulfill regulatory agency requirements for investigational new drug (IND) applications. Interventional agents are tested in confirmatory and specialized assays in high-throughput format (i.e., greater than 96-well plates) with the objective of identifying and characterizing agents that block HIV infection, inhibit HIV gene expression and replication, and/or cure infected cells of HIV infection. Inhibitors of HIV-1 capsid dimerization will be screened.

针对艾滋病毒的新疗法和局部杀菌剂的开发和引入仍然是高公共卫生的重中之重。为了帮助填补这些公共卫生差距，NIAID支持从学术界，私营部门或其他来源出现的有前途的治疗和局部菌心候选者的临床前开发。该合同提供了使用标准和高吞吐量筛选（HTS）格式的生化和基于细胞的测定的产品开发服务。根据本合同提供的服务将有助于各种各样的调查人员获得获得额外资金，获得潜在合作伙伴关系（用于进一步开发或支持I期试验）所需的关键数据，并满足调查公司新药（IND）应用的监管机构要求。在验证性和专业测定中以高通量格式（即，大于96孔板）进行了介入剂的测试，目的是鉴定和表征阻断HIV感染，抑制HIV基因表达和复制和/或治愈HIV感染细胞的HIV感染的药物。 将筛选HIV-1衣壳二聚化的抑制剂。